NPCE · Insider Trading
Neuropace, Inc. Common Stock
Every open-market purchase and sale reported by NPCE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −335 | −$4.68K |
| 2026-09-21 | Patrick F. Williams | Chief Financial Officer | F | −1,162 | −$16.59K |
| 2026-09-04 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,310 | −$19.32K |
| 2026-08-28 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −358 | −$5.06K |
| 2026-08-28 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,126 | −$15.91K |
| 2026-06-25 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −335 | −$5.43K |
| 2026-06-22 | Uri Geiger | Director | A | +789 | +$12.33K |
| 2026-06-22 | Frank M Fischer | Director | A | +1,467 | +$22.93K |
| 2026-06-22 | Rakhi Kumar | Director | A | +989 | +$15.46K |
| 2026-06-05 | Renee Ryan | Director | A | +2,890 | — |
| 2026-06-05 | Rakhi Kumar | Director | A | +2,890 | — |
| 2026-06-05 | Uri Geiger | Director | A | +2,890 | — |
| 2026-06-05 | R Scott Huennekens | Director | A | +2,890 | — |
| 2026-06-05 | Lisa Andrade | Director | A | +2,890 | — |
| 2026-06-05 | Frank M Fischer | Director | A | +2,890 | — |
| 2026-06-04 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,255 | −$19.93K |
| 2026-05-28 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −358 | −$6.11K |
| 2026-05-28 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,126 | −$19.21K |
| 2026-05-19 | Joel Becker | CHIEF EXECUTIVE OFFICER | A | +45,880 | — |
| 2026-05-19 | Patrick F. Williams | Chief Financial Officer | A | +16,820 | — |
| 2026-05-19 | Martha Morrell | CHIEF MEDICAL OFFICER | A | +5,460 | — |
| 2026-03-25 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −1,341 | −$17.80K |
| 2026-03-24 | Uri Geiger | Director | A | +913 | +$11.87K |
| 2026-03-24 | Joseph Lacob | Director | A | +865 | +$11.24K |
| 2026-03-23 | Rakhi Kumar | Director | A | +1,153 | +$14.99K |
| 2026-03-23 | Frank M Fischer | Director | A | +1,826 | +$23.74K |
| 2026-03-04 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −5,023 | −$69.47K |
| 2026-03-04 | Martha Morrell | CHIEF MEDICAL OFFICER | MIXED | −26,340 | −$417.78K |
| 2026-03-02 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −358 | −$5.22K |
| 2026-03-02 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,126 | −$16.42K |
| 2026-02-23 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −3,412 | −$48.93K |
| 2025-12-23 | Uri Geiger | Director | A | +715 | +$11.86K |
| 2025-12-23 | Frank M Fischer | Director | A | +1,431 | +$23.74K |
| 2025-12-23 | Joseph Lacob | Director | A | +678 | +$11.25K |
| 2025-12-23 | Rakhi Kumar | Director | A | +904 | +$15.00K |
| 2025-12-04 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −1,338 | −$22.29K |
| 2025-12-01 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,126 | −$18.58K |
| 2025-12-01 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −357 | −$5.89K |
| 2025-11-24 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −3,051 | −$41.19K |
| 2025-09-22 | Rakhi Kumar | Director | A | +1,509 | +$15.00K |
| 2025-09-22 | Uri Geiger | Director | A | +1,194 | +$11.87K |
| 2025-09-22 | Frank M Fischer | Director | A | +2,389 | +$23.75K |
| 2025-09-22 | Joseph Lacob | Director | A | +1,131 | +$11.24K |
| 2025-09-04 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −1,337 | −$12.51K |
| 2025-08-28 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −357 | −$3.17K |
| 2025-08-28 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | −1,126 | −$10.00K |
| 2025-08-22 | Martha Morrell | CHIEF MEDICAL OFFICER | F | −3,052 | −$26.43K |
| 2025-06-24 | Patrick F. Williams | Chief Financial Officer | A | +51,850 | — |
| 2025-06-24 | Joseph Lacob | Director | A | +11,696 | +$101.21K |
| 2025-06-24 | Uri Geiger | Director | A | +12,036 | +$105.43K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Uri Geiger | Director | 4,451,485 | $57.82M |
| OrbiMed Capital GP VI LLC | 10%+ Owner | 3,272,199 | $42.51M |
| Frank M Fischer | Director | 599,534 | $7.79M |
| Joseph Lacob | Director | 142,928 | $1.86M |
| Joel Becker | CHIEF EXECUTIVE OFFICER | 138,000 | $1.79M |
| Rebecca Kuhn | CHIEF FINANCIAL OFFICER | 131,613 | $1.71M |
| Patrick F. Williams | Chief Financial Officer | 67,508 | $876.93K |
| Martha Morrell | CHIEF MEDICAL OFFICER | 51,357 | $667.13K |
| Rakhi Kumar | Director | 23,039 | $299.28K |
| R Scott Huennekens | Director | 2,890 | $37.54K |
| Lisa Andrade | Director | 2,890 | $37.54K |
| Renee Ryan | Director | 2,890 | $37.54K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NPCE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.